Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The Swiss drug firm Helsinn has started a $50 million venture capital fund to invest in drug, device, and food start-ups. The fund will support firms with early-stage technologies for cancer therapeutics, diagnostics, and supportive care; metabolic and gastrointestinal disorders; and dermatology conditions. Helsinn will invest in 10 to 15 firms, providing scientific and clinical strategy guidance, along with operational and board support. So far, the fund has invested in firms including MEI Pharma, OncoResponse, and QuantuMDx.
This article has been sent to the following recipient: